Stefan Grossauer

Medical University of Vienna — Austria

Medicine · Health Sciences

7h-index273citations51works0.82yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Glioma Diagnosis and Treatment(29), Microtubule and mitosis dynamics(12), Cancer Cells and Metastasis(9), Cell Image Analysis Techniques(7), Spinal Fractures and Fixation Techniques(5)

Publications51 total

Anatomic safeguards and the low risk of vascular injury during percutaneous tricortical S1 pedicle screw fixation – a cadaver study
Scientific Reports·2026Open Access
BRAF/MEK inhibition induces cell state transitions boosting immune checkpoint sensitivity in BRAFV600E-mutant glioma
Cell Reports Medicine·2025· 3 citedOpen Access
CNSC-25. CONCURRENT IMMUNE CHECKPOINT BLOCKADE ENHANCES THE SURVIVAL BENEFIT OF CLINICALLY RELEVANT MAPK PATHWAY INHIBITORS IN A T CELL-DEPENDENT MANNER
Neuro-Oncology·2024Open Access
Why there is a low risk of vascular injury during percutaneous tricortical S1 pedicle screw fixation – A cadaver study
Brain and Spine·2024Open Access
Supplementary Figure S3 from Targeting a Plk1-Controlled Polarity Checkpoint in Therapy-Resistant Glioblastoma-Propagating Cells
2023Open Access
Supplementary Figure Legends from Targeting a Plk1-Controlled Polarity Checkpoint in Therapy-Resistant Glioblastoma-Propagating Cells
2023Open Access
Data from Targeting a Plk1-Controlled Polarity Checkpoint in Therapy-Resistant Glioblastoma-Propagating Cells
2023Open Access
Supplementary Figure S7 from Targeting a Plk1-Controlled Polarity Checkpoint in Therapy-Resistant Glioblastoma-Propagating Cells
2023Open Access
Supplementary Figure S1 from Targeting a Plk1-Controlled Polarity Checkpoint in Therapy-Resistant Glioblastoma-Propagating Cells
2023Open Access
Supplementary Figure S5 from Targeting a Plk1-Controlled Polarity Checkpoint in Therapy-Resistant Glioblastoma-Propagating Cells
2023Open Access
Supplementary Figure S5 from Targeting a Plk1-Controlled Polarity Checkpoint in Therapy-Resistant Glioblastoma-Propagating Cells
2023Open Access
Supplementary Figure S4 from Targeting a Plk1-Controlled Polarity Checkpoint in Therapy-Resistant Glioblastoma-Propagating Cells
2023Open Access
Supplementary Figure S2 from Targeting a Plk1-Controlled Polarity Checkpoint in Therapy-Resistant Glioblastoma-Propagating Cells
2023Open Access
Supplementary Figure S7 from Targeting a Plk1-Controlled Polarity Checkpoint in Therapy-Resistant Glioblastoma-Propagating Cells
2023Open Access
Supplementary Figure S4 from Targeting a Plk1-Controlled Polarity Checkpoint in Therapy-Resistant Glioblastoma-Propagating Cells
2023Open Access
Supplementary Figure S1 from Targeting a Plk1-Controlled Polarity Checkpoint in Therapy-Resistant Glioblastoma-Propagating Cells
2023Open Access
Supplementary Figure S6 from Targeting a Plk1-Controlled Polarity Checkpoint in Therapy-Resistant Glioblastoma-Propagating Cells
2023Open Access
Supplementary Figure Legends from Targeting a Plk1-Controlled Polarity Checkpoint in Therapy-Resistant Glioblastoma-Propagating Cells
2023Open Access
Supplementary Figure S6 from Targeting a Plk1-Controlled Polarity Checkpoint in Therapy-Resistant Glioblastoma-Propagating Cells
2023Open Access
Data from Targeting a Plk1-Controlled Polarity Checkpoint in Therapy-Resistant Glioblastoma-Propagating Cells
2023Open Access
page 1 of 3Next →

Frequent Co-authors

Katharina Koeck(36), Claudia Petritsch(35), Joanna J. Phillips(22), Theodore Nicolaides(22), Robin G. Lerner(21), Banafsheh Kadkhodaei(21), Mitchel S. Berger(21), Rintaro Hashizume(20), Tomoko Ozawa(20), Ian Meyers(19), Maxim Sidorov(19), C. David James(19), Jong‐Whi Park(7), Giles H. Vince(6), Wei Wang(6), Michelle Monje(5), Gerald A. Grant(5), Ian Meyers(4), Laura M. Prolo(4), Mathieu Daynac(3)